BEDMINSTER, N.J. & CHICAGO--(BUSINESS WIRE)--Clinical investigators presented new data from three sub-studies in patients with short bowel syndrome (SBS) who received GATTEX™ (teduglutide) during a 24-week, placebo-controlled Phase 3 clinical trial. Results were presented at the annual Digestive Disease Week (DDW) Congress taking place in Chicago.
